Neratinib (HKI-272)
≥95%(HPLC)
- Product Code: 77678
CAS:
698387-09-6
| Molecular Weight: | 557.04 g./mol | Molecular Formula: | C₃₀H₂₉ClN₆O₃ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD09752958 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
Neratinib is primarily used in the treatment of HER2-positive breast cancer. It is an irreversible tyrosine kinase inhibitor that targets HER2 and EGFR, making it effective in blocking the signaling pathways that promote cancer cell growth. It is often prescribed as an extended adjuvant therapy for patients who have previously undergone trastuzumab-based treatment to reduce the risk of cancer recurrence. Additionally, it is being investigated for its potential in treating other HER2-driven cancers, such as metastatic breast cancer and certain types of non-small cell lung cancer. Its ability to cross the blood-brain barrier also makes it a candidate for treating HER2-positive brain metastases.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White to Light yellow powder to crystal |
| PURITY | 94.5-100 |
| Infrared spectrum | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿1,650.00 |
+
-
|
| 0.025 | 10-20 days | ฿5,760.00 |
+
-
|
| 0.100 | 10-20 days | ฿18,480.00 |
+
-
|
Neratinib (HKI-272)
Neratinib is primarily used in the treatment of HER2-positive breast cancer. It is an irreversible tyrosine kinase inhibitor that targets HER2 and EGFR, making it effective in blocking the signaling pathways that promote cancer cell growth. It is often prescribed as an extended adjuvant therapy for patients who have previously undergone trastuzumab-based treatment to reduce the risk of cancer recurrence. Additionally, it is being investigated for its potential in treating other HER2-driven cancers, such as metastatic breast cancer and certain types of non-small cell lung cancer. Its ability to cross the blood-brain barrier also makes it a candidate for treating HER2-positive brain metastases.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :